Meanwhile, the pressure is mounting; several companies are selling their versions of genetic tests to physicians or directly to the public ( see sidebar).
The mammography debate (whether screening should begin at age 40 or 50 years) is moving this fi eld along as well. "Risk assessment is sexy again because of the issues related to the U.S. Preventive Services Task Force routine mammography recommendations," said Susan M. Domchek, M.D. , associate professor of medicine at the Abramson Cancer Center at the University of Pennsylvania, Philadelphia. The task force did not recommend screening mammography until age 50 years, in contrast to guidelines from some other groups, such as the American Cancer Society. "Every single person would agree that not every woman needs a mammogram at 40. But some do. We need to get better at fi guring out who those women are," said Domchek.
Current Models
"Having the models has been a very positive step," said BCRAT model developer Mitchell H. Gail, M.D., Ph.D., senior investigator in NCI's Division of Cancer Epidemiology and Genetics. "Previously, people had no idea, a very exaggerated idea, or strong underestimation of their risk. At least models are beginning to inform the decision." Now it's important, Gail said, to test their calibration (how accurately a tool estimates the number of cases and noncases) in various populations and to improve their discrimination (how accurately they indicate who will and will not get the disease).
"Women who attend family history clinics would like to be told what they should do in their own life. They don't want to know population-based statistics," Amir said. In a May 19, 2010, article in JNCI, Amir and colleagues compared the ability of six models to assess individuals ' risk of breast cancer over time. Is one better than another? Should a woman at high risk use a different model than one at average risk?
These models can go only so far because they all rely on known risk factors, even though up to 60% of breast cancers occur in women with no known risk factors. Plus, most do not include many of the known risk factors unrelated to family history, such as hormone use, mammographic density, obesity, and diet.
No model really outshone the others, according to Amir's review. Several underestimated risk of breast cancer, especially in women with a single fi rst-degree relative with the disease. Amir's team developed a fl owchart to help physicians decide which model may make more sense for their patients. They noted that researchers are making incremental improvements to the models, such as adding hormone use, although the improved versions still need validation in large populations.
Adding SNPs?
Adding genetic variants is one way to improve the models. "With the rapidly emerging information on common genetic variants that increase risk, it's a natural time to ask, 'Could we do better? ' " said Patricia Hartge, Sc. 
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article, looked at whether adding any known SNPs to risk assessment tools is worthwhile.
"While SNPs may be an important clue to biological mechanisms and may eventually have a big payoff for understanding biology, the question was, 'Could they be used immediately for improving discriminatory accuracy of these models and making better public health decisions? ' " said Gail. The answer is no.
The researchers compared 5,590 case patients and 5,998 control subjects, aged 50 -79 years, from the Nurse's Health Study; Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Study; Women's Health Initiative; American Cancer Society Cancer Prevention Study II Nutrition Cohort; and a case -control study in Poland. They looked at 10 common genetic variants associated with breast cancer; adding these variants to the Gail model yielded a modest improvement over using the Gail model alone.
"Although you do get improvement, this still doesn't get us anywhere near the level of discrimination, or reliable prediction, that most women need to make clinical decisions," Hartge said. The study was about the average woman, not those with family history or BRCA1 or BRCA2 mutations. Domchek, however, is looking specifi cally at women with BRCA1 and BRCA2 mutations to see whether genetic variants can better stratify their risk. In a May 14 Human Molecular Genetics online article, she and colleagues reported differences in genetic variants between carriers of BRCA1 and BRCA2 mutations. "We've known for a long time that there's great variability of penetrance in mutation carriers. Some get it at age 30, some later," she said. "My dream is that we'll be able to help women make their timing of prophylactic surgery, especially oophorectomy, more precise based on their risk. But we're not close to that yet."
Back to the Future
Georgetown's Furth isn't discouraged that studies aren't further along. "The world needs to understand that the genome is very complex. Maybe we should be looking at different SNPs, or maybe it's more than SNPs, such as small RNAs or methylation. Maybe there are interacting factors."
In a move toward her vision of early testing of breast tissue, Furth has developed mouse models of breast cancer to narrow her search for the most important genes. In a May 15 article in Cancer Research , she reported that small variations in expression of the genes for p53 and estrogen receptor ␣ appear to be associated with breast cancer development. She can see them used together as biomarkers to predict future breast cancer risk.
There's still a lot to do, however: Validate mouse model fi ndings for human disease, fi gure out how to do the test in people, determine how many cells are needed. After that, researchers would have to determine when and how often women would need the test. Maybe it could be like a Pap smear, Furth said: three negative results and then testing less often. Finally, "Down the pike, I hope to see some version of SNP panels, but maybe not the ones we have now." marketing experts would need to fi gure out whether such a test would be acceptable to women and whether insurers would pay.
Meanwhile, the private sector is moving forward. Companies such as 23andme and Navigenics offer genetic screening tests directly to consumers through the Internet, a practice that the U.S. Food and Drug Administration is now questioning (see sidebar 
Selling Genetic Testing to Consumers
The genetic testing genie is emerging from the bottle and regulators are trying to contain it
• Pathway Genomics announced in May that it would sell kits that assess genetic risk for several diseases, including breast cancer, direct to consumers through 60,000 Walgreens stores. The U.S. Food and Drug Administration immediately responded that FDA approval is required, and the launch was put on hold until the company resolves the issue with the FDA. Congress has announced an investigation of personal genetic test kits as well.
• A few companies are selling similar direct-to-consumer genetic testing kits on the Internet. In June, the FDA sent letters to five companies -23andme, Navigenics, deCODE Genetics, Illumina, and Knome -saying that the kits are considered medical devices and require FDA approval for marketing. The agency did not demand that the kits be taken off the market immediately.
• Another company, Intergenetics, offers its Oncovue test only to physicians ( see news story).
• The University of California, Berkeley, announced in May that it will offer genetic testing to incoming freshmen. Students can have their saliva checked for genes that regulate the ability to metabolize alcohol, lactose, and folates. The school says that it's an effort to engage the students in a common intellectual experience, but ethicists, including Arthur Caplan, Ph.D., at the University of Pennsylvania, Philadelphia, have called making genetic test results available without counseling a mistake. What if a student learned that he was not alcohol intolerant and decided that he could binge drink?
